|
1
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Birchmeier C and Gherardi E: Developmental
roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends
Cell Biol. 8:404–410. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huh CG, Factor VM, Sánchez A, Uchida K,
Conner EA and Thorgeirsson SS: Hepatocyte growth factor/c-met
signaling pathway is required for efficient liver regeneration and
repair. Proc Natl Acad Sci USA. 101:4477–4482. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suzuki K, Hayashi N, Yamada Y, Yoshihara
H, Miyamoto Y, Ito Y, Ito T, Katayama K, Sasaki Y, Ito A, et al:
Expression of the c-met protooncogene in human hepatocellular
carcinoma. Hepatology. 20:1231–1236. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kiss A, Wang NJ, Xie JP and Thorgeirsson
SS: Analysis of transforming growth factor (TGF)-alpha/epidermal
growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta
receptor type II, and p53 expression in human hepatocellular
carcinomas. Clin Cancer Res. 3:1059–1066. 1997.PubMed/NCBI
|
|
8
|
Suárez-Causado A, Caballero-Díaz D,
Bertrán E, Roncero C, Addante A, García-Álvaro M, Fernández M,
Herrera B, Porras A, Fabregat I and Sánchez A: HGF/c-Met signaling
promotes liver progenitor cell migration and invasion by an
epithelial-mesenchymal transition-independent, phosphatidyl
inositol-3 kinase-dependent pathway in an in vitro model. Biochim
Biophys Acta. 1853:2453–2463. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goyal L, Muzumdar MD and Zhu AX: Targeting
the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res.
19:2310–2318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hua Z, Wu C, Fan G, Tang Z and Cao F: The
antibacterial activity and mechanism of ginkgolic acid C15:1. BMC
Biotechnol. 17:52017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lü JM, Yan S, Jamaluddin S, Weakley SM,
Liang Z, Siwak EB, Yao Q and Chen C: Ginkgolic acid inhibits HIV
protease activity and HIV infection in vitro. Med Sci Monit.
18:BR293–BR298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li R, Shen Y, Zhang X, Ma M, Chen B and
van Beek TA: Efficient purification of ginkgolic acids from Ginkgo
biloba leaves by selective adsorption on Fe3O4 magnetic
nanoparticles. J Nat Prod. 77:571–575. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li L, Yao QQ, Xu SY, Hu HH, Shen Q, Tian
Y, Pan LY, Zhou H, Jiang HD, Lu C, et al: Cyclosporin A affects the
bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
Eur J Pharm Biopharm. 88:759–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma J, Duan W, Han S, Lei J, Xu Q, Chen X,
Jiang Z, Nan L, Li J, Chen K, et al: Ginkgolic acid suppresses the
development of pancreatic cancer by inhibiting pathways driving
lipogenesis. Oncotarget. 6:20993–21003. 2015.PubMed/NCBI
|
|
16
|
Liu Y, Yang B, Zhang L, Cong X, Liu Z, Hu
Y, Zhang J and Hu H: Ginkgolic acid induces interplay between
apoptosis and autophagy regulated by ROS generation in colon
cancer. Biochem Biophys Res Commun. 498:246–253. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiao L, Zheng J, Jin X, Wei G, Wang G, Sun
X and Li X: Ginkgolic acid inhibits the invasiveness of colon
cancer cells through AMPK activation. Oncol Lett. 14:5831–5838.
2017.PubMed/NCBI
|
|
18
|
Hamdoun S and Efferth T: Ginkgolic acids
inhibit migration in breast cancer cells by inhibition of NEMO
sumoylation and NF-κB activity. Oncotarget. 8:35103–35115. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Venepalli NK and Goff L: Targeting the
HGF-cMET axis in hepatocellular carcinoma. Int J Hepatol.
2013:3416362013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Illam SP, Narayanankutty A, Mathew SE,
Valsalakumari R, Jacob RM and Raghavamenon AC: Epithelial
mesenchymal transition in cancer progression: Prev entive
phytochemicals. Recent Pat Anticancer Drug Discov. 12:234–246.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cha C, Fong Y, Jarnagin WR, Blumgart LH
and DeMatteo RP: Predictors and patterns of recurrence after
resection of hepatocellular carcinoma. J Am Coll Surg. 197:753–758.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martínez Ares D, Suárez López FJ, Souto
Ruzo J, Otero Ferreiro A, Gómez Gutiérrez M, González Conde B,
Fernández Sellés C, Gala López B, Arnal Monreal F and Vázquez
Iglesias JL: Liver transplantation in patients with hepatocellular
carcinoma: Factors implicated in tumor relapse. Rev Esp Enferm Dig.
96:22–31. 2004.(In English, Spanish). PubMed/NCBI
|
|
24
|
Yap TA, Sandhu SK, Alam SM and de Bono JS:
HGF/c-MET targeted therapeutics: Novel strategies for cancer
medicine. Curr Drug Targets. 12:2045–2058. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Comoglio PM, Giordano S and Trusolino L:
Drug development of MET inhibitors: Targeting oncogene addiction
and expedience. Nat Rev Drug Discov. 7:504–516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaposi-Novak P, Lee JS, Gòmez-Quiroz L,
Coulouarn C, Factor VM and Thorgeirsson SS: Met-regulated
expression signature defines a subset of human hepatocellular
carcinomas with poor prognosis and aggressive phenotype. J Clin
Invest. 116:1582–1595. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu FS, Zheng SS, Wu LJ, Ding W, Ma ZM,
Wang ZM, Teng LS and Zhao WH: Study on the prognostic value of
hepatocyte growth factor and c-met for patients with hepatocellular
carcinoma. Zhonghua Wai Ke Za Zhi. 44:603–608. 2006.(In Chinese).
PubMed/NCBI
|
|
28
|
Munshi N, Jeay S, Li Y, Chen CR, France
DS, Ashwell MA, Hill J, Moussa MM, Leggett DS and Li CJ: ARQ 197, a
novel and selective inhibitor of the human c-Met receptor tyrosine
kinase with antitumor activity. Mol Cancer Ther. 9:1544–1553. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santoro A, Rimassa L, Borbath I, Daniele
B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs
FT, Weiss A, et al: Tivantinib for second-line treatment of
advanced hepatocellular carcinoma: A randomised, placebo-controlled
phase 2 study. Lancet Oncol. 14:55–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–90. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia
XF, Sun X, Li GG, Hu QD, Fu QH and Liang TB: Hypoxia-induced
epithelial-to-mesenchymal transition in hepatocellular carcinoma
induces an immunosuppressive tumor microenvironment to promote
metastasis. Cancer Res. 76:818–830. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ogunwobi OO and Liu C: Hepatocyte growth
factor upregulation promotes carcinogenesis and
epithelial-mesenchymal transition in hepatocellular carcinoma via
Akt and COX-2 pathways. Clin Exp Metastasis. 28:721–731. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam
D, Lee J, Lee SG, Yang WM, Um JY, et al: Ginkgolic acid inhibits
invasion and migration and TGF-β-induced EMT of lung cancer cells
through PI3K/Akt/mTOR inactivation. J Cell Physiol. 232:346–354.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou C, Li X, Du W, Feng Y, Kong X, Li Y,
Xiao L and Zhang P: Antitumor effects of ginkgolic acid in human
cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax
ratio to induce apoptosis. Chemotherapy. 56:393–402. 2010.
View Article : Google Scholar : PubMed/NCBI
|
